Sean McCutcheon
Stock Analyst at Raymond James
(0.27)
# 4,282
Out of 4,981 analysts
10
Total ratings
22.22%
Success rate
-17.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean McCutcheon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Assumes: Strong Buy | $72 | $46.55 | +54.67% | 1 | Sep 12, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $5.00 | +140.00% | 1 | Jul 11, 2025 | |
| JANX Janux Therapeutics | Initiates: Outperform | $65 | $24.05 | +170.27% | 1 | Jul 11, 2025 | |
| CMPX Compass Therapeutics | Reinstates: Outperform | $9 | $3.57 | +152.10% | 1 | Jul 1, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Outperform | $11 | $3.25 | +238.46% | 1 | Jul 1, 2025 | |
| ENGN enGene Holdings | Initiates: Outperform | $23 | $5.71 | +302.80% | 1 | Nov 27, 2024 | |
| XNCR Xencor | Maintains: Strong Buy | $58 → $40 | $8.60 | +365.12% | 1 | Jun 14, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $92 → $70 | $51.13 | +36.91% | 2 | May 23, 2024 | |
| LEGN Legend Biotech | Initiates: Outperform | $86 | $33.11 | +159.74% | 1 | Mar 13, 2024 |
Revolution Medicines
Sep 12, 2025
Assumes: Strong Buy
Price Target: $72
Current: $46.55
Upside: +54.67%
Vir Biotechnology
Jul 11, 2025
Initiates: Outperform
Price Target: $12
Current: $5.00
Upside: +140.00%
Janux Therapeutics
Jul 11, 2025
Initiates: Outperform
Price Target: $65
Current: $24.05
Upside: +170.27%
Compass Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $9
Current: $3.57
Upside: +152.10%
Black Diamond Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $11
Current: $3.25
Upside: +238.46%
enGene Holdings
Nov 27, 2024
Initiates: Outperform
Price Target: $23
Current: $5.71
Upside: +302.80%
Xencor
Jun 14, 2024
Maintains: Strong Buy
Price Target: $58 → $40
Current: $8.60
Upside: +365.12%
Cytokinetics
May 23, 2024
Maintains: Outperform
Price Target: $92 → $70
Current: $51.13
Upside: +36.91%
Legend Biotech
Mar 13, 2024
Initiates: Outperform
Price Target: $86
Current: $33.11
Upside: +159.74%